Status:
UNKNOWN
Trimetazidine As a Potential Adjuvant Therapy in Acute Aluminum Phosphide Poisoning-induced Cardiotoxicity
Lead Sponsor:
Tanta University
Conditions:
Aluminum Phosphide Poisoning
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The aim of the present study is to evaluate the potential adjuvant therapeutic effect of trimetazidine in treatment of acute AlP poisoning-induced cardiotoxicity.
Detailed Description
Aluminium phosphide (AlP) is an inorganic phosphide. It is used as a fumigant to protect stored grains from insects, rodents and other pests.It is a solid fumigant widely used in Egypt as a grain pres...
Eligibility Criteria
Inclusion
- Patients included in this study will be diagnosed as acute aluminum phosphide poisoning by history and clinical pictures.
- Age is18 years or older.
Exclusion
- Pregnant and lactating women.
- Patients with ingestion or exposure to other substances in addition to aluminum phosphide.
- Patients with other major medical conditions (e.g. cardiovascular disease, diabetes mellitus, renal or hepatic failure).
Key Trial Info
Start Date :
February 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2021
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04702906
Start Date
February 1 2021
End Date
July 1 2021
Last Update
January 11 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.